ABSTRACT
Methylene blue (MB) is known to have trypanocidal activity. We tested the interactions of MB with a number of trypanosomatid-specific molecules of the antioxidant metabolism. At pH 7, trypanothione and other (di)thiols were oxidized to disulfides by the phenothiazine drug. MB inhibited Trypanosoma cruzi trypanothione reductase (TR) (K(i)=1.9 microM), and served as a significant subversive substrate of this enzyme (K(M)=30 microM, k(cat)=4.9s(-1)). With lipoamide dehydrogenase, the second thiol-generating flavoenzyme of T. cruzi, the catalytic efficiency for MB reduction was found to be almost 10(6)M(-1)s(-1). When the system MB-enzyme-molecular oxygen acts as a NAD(P)H-driven redox cycler, a reactive oxygen species, H(2)O(2) or superoxide, is produced in each cycle. Since MB is an affordable, available, and accessible drug it might be tested--alone or in drug combinations--against trypanosomatid-caused diseases of animal and man.
Subject(s)
Methylene Blue/pharmacokinetics , Sulfhydryl Compounds/metabolism , Trypanocidal Agents/pharmacokinetics , Trypanosoma/enzymology , Animals , Antioxidants/metabolism , Catalysis , Dihydrolipoamide Dehydrogenase/antagonists & inhibitors , Glutathione/analogs & derivatives , Glutathione/metabolism , NADH, NADPH Oxidoreductases/antagonists & inhibitors , Oxidation-Reduction , Reactive Oxygen Species/metabolism , Spermidine/analogs & derivatives , Spermidine/metabolismABSTRACT
Proteins containing the 21st amino acid selenocysteine (Sec) are present in the three domains of life. However, within lower eukaryotes, particularly parasitic protists, the dependence on the trace element selenium is variable as many organisms lost the ability to utilize Sec. Herein, we analyzed the genomes of Trypanosoma and Leishmania for the presence of genes coding for Sec-containing proteins. The selenoproteomes of these flagellated protozoa have three selenoproteins, including distant homologs of mammalian SelK and SelT, and a novel multidomain selenoprotein designated SelTryp. In SelK and SelTryp, Sec is near the C-terminus, and in all three selenoproteins, it is within predicted redox motifs. SelTryp has neither Sec- nor cysteine-containing homologs in the human host and appears to be a Kinetoplastida-specific protein. The use of selenium for protein synthesis was verified by metabolically labeling Trypanosoma cells with 75Se. In addition, genes coding for components of the Sec insertion machinery were identified in the Kinetoplastida genomes. Finally, we found that Trypanosoma brucei brucei cells were highly sensitive to auranofin, a compound that specifically targets selenoproteins. Overall, these data establish that Trypanosoma, Leishmania and likely other Kinetoplastida utilize and depend on the trace element selenium, and this dependence is due to occurrence of selenium in at least three selenoproteins.
Subject(s)
Genome, Protozoan , Leishmania/genetics , Protozoan Proteins/genetics , Selenium/metabolism , Selenoproteins/genetics , Trypanosoma/genetics , Amino Acid Sequence , Animals , Auranofin/pharmacology , Base Sequence , Computational Biology , Genomics , Leishmania/metabolism , Molecular Sequence Data , Phylogeny , Proteome/genetics , Protozoan Proteins/chemistry , RNA, Protozoan/chemistry , RNA, Transfer/classification , Selenoproteins/chemistry , Sequence Alignment , Trypanosoma/drug effects , Trypanosoma/metabolismABSTRACT
The use of selenocysteine (Sec) as the 21st amino acid in the genetic code has been described in all three major domains of life. However, within eukaryotes, selenoproteins are only known in animals and algae. In this study, we characterized selenoproteomes and Sec insertion systems in protozoan Apicomplexa parasites. We found that among these organisms, Plasmodium and Toxoplasma utilized Sec, whereas Cryptosporidium did not. However, Plasmodium had no homologs of known selenoproteins. By searching computationally for evolutionarily conserved selenocysteine insertion sequence (SECIS) elements, which are RNA structures involved in Sec insertion, we identified four unique Plasmodium falciparum selenoprotein genes. These selenoproteins were incorrectly annotated in PlasmoDB, were conserved in other Plasmodia and had no detectable homologs in other species. We provide evidence that two Plasmodium SECIS elements supported Sec insertion into parasite and endogenous selenoproteins when they were expressed in mammalian cells, demonstrating that the Plasmodium SECIS elements are functional and indicating conservation of Sec insertion between Apicomplexa and animals. Dependence of the plasmodial parasites on selenium suggests possible strategies for antimalarial drug development.
Subject(s)
Plasmodium falciparum/genetics , Protozoan Proteins/genetics , Selenocysteine/metabolism , Selenoproteins/genetics , Amino Acid Sequence , Animals , Base Sequence , Evolution, Molecular , Malaria/drug therapy , Mice , Molecular Sequence Data , NIH 3T3 Cells , Plasmodium/genetics , Plasmodium falciparum/metabolism , Proteome/chemistry , Proteome/genetics , Proteome/metabolism , Protozoan Proteins/chemistry , Protozoan Proteins/metabolism , RNA, Transfer, Amino Acyl/chemistry , Regulatory Sequences, Ribonucleic Acid , Selenoproteins/chemistry , Selenoproteins/metabolism , Sequence AlignmentABSTRACT
The catalytic activity of selenocysteine-containing thioredoxin reductases can be mimicked by cysteine-variants if the local environment at the C-terminal redox center supports thiol activation. This concept of a linear catalytic site was challenged by structural data suggesting that the invariant residue His106 functions as a base catalyst for the dithiol-disulphide exchange reaction between enzyme and substrate. As reported here, we changed His106 to asparagine, glutamine, and phenylalanine in various C-terminal mutants of Drosophila melanogaster thioredoxin reductase. The catalytic activity dropped considerably, yet pH-profiles did not reveal differences, rendering a function for His106 as a base catalyst unlikely. Interestingly, the phenylalanine-mutants, designed as negative controls were the most active mutants which suggests rather a structural role of His106.
Subject(s)
Histidine/metabolism , Thioredoxin-Disulfide Reductase/metabolism , Amino Acid Sequence , Animals , Catalysis , Drosophila melanogaster , Models, Molecular , Molecular Sequence Data , Protein Conformation , Sequence Homology, Amino Acid , Thioredoxin-Disulfide Reductase/chemistryABSTRACT
The human selenoprotein thioredoxin reductase is involved in antioxidant defense and DNA synthesis. As increased thioredoxin reductase levels are associated with drug sensitivity to cisplatin and drug resistance in tumor cells, this enzyme represents a promising target for the development of cytostatic agents. To optimize the potential of the widely used cisplatin to inhibit the human thioredoxin reductase and therefore to overcome cisplatin resistance, we developed and synthesized four cis-diamminedichloroplatinum complexes of the lead 5-nitro-2-furancarbohydrazide 8 selected from high-throughput screening. Detailed kinetics revealed that the isolated fragments, 5-nitro-2-furancarbohydrazide and cisplatin itself, bind with micromolar affinities at two different subsites of the human enzyme. By tethering both fragments four nitrofuran-based cis-diamminedichloroplatinum complexes 13a-c and 20 were synthesized and identified as bi-ligand irreversible inhibitors of the human enzyme with nanomolar affinities. Studies with mutant enzymes clearly demonstrate the penultimate selenocysteine residue as the prime target of the synthesized cis-diamminedichloroplatinum complexes.
Subject(s)
Antineoplastic Agents/chemical synthesis , Furans/chemical synthesis , Hydrazines/chemical synthesis , Organoplatinum Compounds/chemical synthesis , Thioredoxin-Disulfide Reductase/antagonists & inhibitors , Animals , Antineoplastic Agents/chemistry , Antineoplastic Agents/pharmacology , Cell Line, Tumor , Drosophila melanogaster , Drug Screening Assays, Antitumor , Furans/chemistry , Furans/pharmacology , Humans , Hydrazines/chemistry , Hydrazines/pharmacology , Kinetics , Mice , Nitroreductases/chemistry , Organoplatinum Compounds/chemistry , Organoplatinum Compounds/pharmacology , Structure-Activity Relationship , Thioredoxin-Disulfide Reductase/chemistry , Time FactorsSubject(s)
Placenta/enzymology , Thioredoxin-Disulfide Reductase/antagonists & inhibitors , Thioredoxin-Disulfide Reductase/isolation & purification , Auranofin/pharmacology , Chromatography, DEAE-Cellulose , Chromatography, Gel , Crystallization , Dithionitrobenzoic Acid/metabolism , Enzyme Inhibitors/pharmacology , Female , Glutathione Disulfide/metabolism , Humans , In Vitro Techniques , Indicators and Reagents , NADP/metabolism , Oxidation-Reduction , Pregnancy , Thioredoxin-Disulfide Reductase/metabolismABSTRACT
Methylene blue (MB) has experienced a renaissance mainly as a component of drug combinations against Plasmodium falciparum malaria. Here, we report biochemically relevant pharmacological data on MB such as rate constants for the uncatalyzed reaction of MB at pH 7.4 with cellular reductants like NAD(P)H (k = 4 M(-1) s(-1)), thioredoxins (k = 8.5 to 26 M(-1) s(-1)), dihydrolipoamide (k = 53 M(-1) s(-1)), and slowly reacting glutathione. As the disulfide reductases are prominent targets of MB, optical tests for enzymes reducing MB at the expense of NAD(P)H under aerobic conditions were developed. The product leucomethylene blue (leucoMB) is auto-oxidized back to MB at pH 7 but can be stabilized by enzymes at pH 5.0, which makes this colorless compound an interesting drug candidate. MB was found to be an inhibitor and/or a redox-cycling substrate of mammalian and P. falciparum disulfide reductases, with the kcat values ranging from 0.03 s(-1) to 10 s(-1) at 25 degrees C. Kinetic spectroscopy of mutagenized glutathione reductase indicates that MB reduction is conducted by enzyme-bound reduced flavin rather than by the active-site dithiol Cys58/Cys63. The enzyme-catalyzed reduction of MB and subsequent auto-oxidation of the product leucoMB mean that MB is a redox-cycling agent which produces H2O2 at the expense of O2 and of NAD(P)H in each cycle, turning the antioxidant disulfide reductases into pro-oxidant enzymes. This explains the terms subversive substrate or turncoat inhibitor for MB. The results are discussed in cell-pathological and clinical contexts.
Subject(s)
Disulfides/metabolism , Methylene Blue/metabolism , Oxidoreductases/metabolism , Plasmodium falciparum/drug effects , Plasmodium falciparum/enzymology , Protozoan Proteins/metabolism , Aerobiosis , Animals , Binding Sites , Humans , Hydrogen-Ion Concentration , Kinetics , Methylene Blue/analogs & derivatives , Methylene Blue/chemistry , Methylene Blue/pharmacology , Oxidation-Reduction , Oxidoreductases/antagonists & inhibitors , Oxidoreductases/chemistry , Protozoan Proteins/chemistry , Substrate SpecificityABSTRACT
Hereditary glutathione reductase (GR) deficiency was found in only 2 cases when testing more than 15 000 blood samples. We have investigated the blood cells of 2 patients (1a and 1b) in a previously described family suffering from favism and cataract and of a novel patient (2) presenting with severe neonatal jaundice. Red blood cells and leukocytes of the patients in family 1 did not contain any GR activity, and the GR protein was undetectable by Western blotting. Owing to a 2246-bp deletion in the patients' DNA, translated GR is expected to lack almost the complete dimerization domain, which results in unstable and inactive enzyme. The red blood cells from patient 2 did not exhibit GR activity either, but the patient's leukocytes contained some residual activity that correlated with a weak protein expression. Patient 2 was found to be a compound heterozygote, with a premature stop codon on one allele and a substitution of glycine 330, a highly conserved residue in the superfamily of NAD(P)H-dependent disulfide reductases, into alanine on the other allele. Studies on recombinant GR G330A revealed a drastically impaired thermostability of the protein. This is the first identification of mutations in the GR gene causing clinical GR deficiency.
Subject(s)
Cataract/genetics , Favism/genetics , Genetic Diseases, Inborn/genetics , Glutathione Reductase/deficiency , Jaundice, Neonatal/genetics , Sequence Deletion , Alleles , Amino Acid Substitution , Cataract/enzymology , Child, Preschool , Codon, Nonsense/genetics , Erythrocytes/enzymology , Favism/enzymology , Female , Genetic Diseases, Inborn/enzymology , Glutathione Reductase/chemistry , Heterozygote , Humans , Infant, Newborn , Jaundice, Neonatal/enzymology , Leukocytes/enzymology , Male , Middle Aged , Protein Structure, Quaternary , Protein Structure, TertiaryABSTRACT
4',5'-Dibromo-2',7'-dinitrofluorescein, a red dye commonly referred to as eosin B, inhibits Toxoplasma gondii in both enzymatic and cell culture studies with a 50% inhibitory concentration (IC(50)) of 180 microM. As a non-active-site inhibitor of the bifunctional T. gondii dihydrofolate reductase-thymidylate synthase (DHFR-TS), eosin B offers a novel mechanism for inhibition of the parasitic folate biosynthesis pathway. In the present study, eosin B was further evaluated as a potential antiparasitic compound through in vitro and cell culture testing of its effects on Plasmodium falciparum. Our data revealed that eosin B is a highly selective, potent inhibitor of a variety of drug-resistant malarial strains, with an average IC(50) of 124 nM. Furthermore, there is no indication of cross-resistance with other clinically utilized compounds, suggesting that eosin B is acting via a novel mechanism. The antimalarial mode of action appears to be multifaceted and includes extensive damage to membranes, the alteration of intracellular organelles, and enzymatic inhibition not only of DHFR-TS but also of glutathione reductase and thioredoxin reductase. In addition, preliminary studies suggest that eosin B is also acting as a redox cycling compound. Overall, our data suggest that eosin B is an effective lead compound for the development of new, more effective antimalarial drugs.
Subject(s)
Antimalarials/pharmacology , Fluoresceins/pharmacology , Plasmodium falciparum/drug effects , Animals , Antimalarials/pharmacokinetics , Cell Line , Drug Resistance , Eosine I Bluish , Fibroblasts/parasitology , Fluoresceins/pharmacokinetics , Glutathione Reductase/antagonists & inhibitors , Glutathione Reductase/metabolism , Humans , Multienzyme Complexes/antagonists & inhibitors , Multienzyme Complexes/metabolism , Plasmodium falciparum/enzymology , Plasmodium falciparum/growth & development , Plasmodium falciparum/metabolism , Tetrahydrofolate Dehydrogenase/metabolism , Thioredoxin-Disulfide Reductase/antagonists & inhibitors , Thioredoxin-Disulfide Reductase/metabolism , Thymidylate Synthase/antagonists & inhibitors , Thymidylate Synthase/metabolismABSTRACT
The thioredoxin system-formed by thioredoxin reductase and its characteristic substrate thioredoxin-is an important constituent of the intracellular redox milieu. Interactions with many different metabolic pathways such as DNA-synthesis, selenium metabolism, and the antioxidative network as well as significant species differences render this system an attractive target for chemotherapeutic approaches in many fields of medicine-ranging from infectious diseases to cancer therapy. In this review we will present and evaluate the preclinical and clinical results available today. Current trends in drug development are emphasized.
Subject(s)
Thioredoxin-Disulfide Reductase/metabolism , Thioredoxins/metabolism , Amino Acid Sequence , Animals , Antioxidants/metabolism , Humans , Molecular Sequence Data , Neoplasms/metabolism , Organ Specificity , Oxidation-Reduction , Substrate Specificity , Thioredoxin-Disulfide Reductase/antagonists & inhibitors , Thioredoxin-Disulfide Reductase/classification , Thioredoxins/antagonists & inhibitors , Thioredoxins/classificationABSTRACT
Biochemical and clinical evidence indicates that monomethylated selenium compounds are crucial for the tumor preventive effects of the trace element selenium and that methylselenol (CH(3)SeH) is a key metabolite. As suggested by Ganther (Ganther, H. E. (1999) Carcinogenesis 20, 1657-1666), methylselenol and its precursor methylseleninate might exert their effects by inhibition of the selenoenzyme thioredoxin reductase via the irreversible formation of a diselenide bridge. Here we report that methylseleninate does not act as an inhibitor of mammalian thioredoxin reductase but is in fact an excellent substrate (K(m) of 18 microm, k(cat) of 23 s(-1)), which is reduced by the enzyme according to the equation 2 NADPH + 2 H(+) + CH(3)SeO(2)H --> 2 NADP(+) + 2 H(2)O + CH(3)SeH. The selenium-containing product of this reaction was identified by mass spectrometry. Nascent methylselenol was found to efficiently reduce both H(2)O(2) and glutathione disulfide. The implications of these findings for the antitumor activity of selenium are discussed. Methylseleninate was a poor substrate not only for human glutathione reductase but also for the non-selenium thioredoxin reductases enzymes from Drosophila melanogaster and Plasmodium falciparum. This suggests that the catalytic selenocysteine residue of mammalian thioredoxin reductase is essential for methylseleninate reduction.
Subject(s)
Antineoplastic Agents/pharmacology , Organoselenium Compounds/chemistry , Organoselenium Compounds/metabolism , Selenium/pharmacology , Thioredoxin-Disulfide Reductase/antagonists & inhibitors , Thioredoxin-Disulfide Reductase/metabolism , Animals , Catalysis , Dithionitrobenzoic Acid/pharmacology , Drosophila melanogaster/enzymology , Glutathione Disulfide/chemistry , Glutathione Reductase/metabolism , Humans , Hydrogen Peroxide/pharmacology , Kinetics , Mass Spectrometry , Mice , Models, Biological , Models, Chemical , Peroxidase/metabolism , Placenta/metabolism , Plasmodium falciparum/enzymology , Protein Binding , Protein Structure, Tertiary , Selenocysteine/chemistry , Silver/chemistry , Substrate Specificity , Thioredoxins/metabolism , Time FactorsABSTRACT
The mosquito, Anopheles gambiae, is an important vector of Plasmodium falciparum malaria. Full genome analysis revealed that, as in Drosophila melanogaster, the enzyme glutathione reductase is absent in A. gambiae and functionally substituted by the thioredoxin system. The key enzyme of this system is thioredoxin reductase-1, a homodimeric FAD-containing protein of 55.3 kDa per subunit, which catalyses the reaction NADPH + H+ + thioredoxin disulfide-->NADP+ + thioredoxin dithiol. The A. gambiae trxr gene is located on chromosome X as a single copy; it represents three splice variants coding for two cytosolic and one mitochondrial variant. The predominant isoform, A. gambiae thioredoxin reductase-1, was recombinantly expressed in Escherichia coli and functionally compared with the wild-type enzyme isolated in a final yield of 1.4 U.ml(-1) of packed insect cells. In redox titrations, the substrate A. gambiae thioredoxin-1 (Km=8.5 microm, kcat=15.4 s(-1) at pH 7.4 and 25 degrees C) was unable to oxidize NADPH-reduced A. gambiae thioredoxin reductase-1 to the fully oxidized state. This indicates that, in contrast to other disulfide reductases, A. gambiae thioredoxin reductase-1 oscillates during catalysis between the four-electron reduced state and a two-electron reduced state. The thioredoxin reductases of the malaria system were compared. A. gambiae thioredoxin reductase-1 shares 52% and 45% sequence identity with its orthologues from humans and P. falciparum, respectively. A major difference among the three enzymes is the structure of the C-terminal redox centre, reflected in the varying resistance of catalytic intermediates to autoxidation. The relevant sequences of this centre are Thr-Cys-Cys-SerOH in A. gambiae thioredoxin reductase, Gly-Cys-selenocysteine-GlyOH in human thioredoxin reductase, and Cys-X-X-X-X-Cys-GlyOH in the P. falciparum enzyme. These differences offer an interesting approach to the design of species-specific inhibitors. Notably, A. gambiae thioredoxin reductase-1 is not a selenoenzyme but instead contains a highly unusual redox-active Cys-Cys sequence.
Subject(s)
Anopheles/enzymology , Plasmodium falciparum/enzymology , Thioredoxin-Disulfide Reductase/metabolism , Amino Acid Sequence , Animals , Cloning, Molecular , Humans , Insect Vectors , Malaria, Falciparum/parasitology , Malaria, Falciparum/transmission , Mass Spectrometry , Molecular Sequence Data , Peptide Mapping , Sequence Homology, Amino Acid , Thioredoxin-Disulfide Reductase/chemistry , Thioredoxin-Disulfide Reductase/geneticsABSTRACT
Selenium, an essential trace element for mammals, is incorporated into a selected class of selenoproteins as selenocysteine. All known isoenzymes of mammalian thioredoxin (Trx) reductases (TrxRs) employ selenium in the C-terminal redox center -Gly-Cys-Sec-Gly-COOH for reduction of Trx and other substrates, whereas the corresponding sequence in Drosophila melanogaster TrxR is -Ser-Cys-Cys-Ser-COOH. Surprisingly, the catalytic competence of these orthologous enzymes is similar, whereas direct Sec-to-Cys substitution of mammalian TrxR, or other selenoenzymes, yields almost inactive enzyme. TrxRs are therefore ideal for studying the biology of selenocysteine by comparative enzymology. Here we show that the serine residues flanking the C-terminal Cys residues of Drosophila TrxRs are responsible for activating the cysteines to match the catalytic efficiency of a selenocysteine-cysteine pair as in mammalian TrxR, obviating the need for selenium. This finding suggests that the occurrence of selenoenzymes, which implies that the organism is selenium-dependent, is not necessarily associated with improved enzyme efficiency. Our data suggest that the selective advantage of selenoenzymes is a broader range of substrates and a broader range of microenvironmental conditions in which enzyme activity is possible.